Previous close | 18.00 |
Open | 18.00 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 190.00 |
Expiry date | 2025-01-17 |
Day's range | 18.00 - 18.00 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Detailed Analysis of Repligen's Financial Performance and Market Positioning
Repligen (RGEN) delivered earnings and revenue surprises of -3.45% and 1.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The compa